First-in-Human Study of DS-1471a in Advanced Solid Tumors

Daiichi Sankyo is conducting a phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DS-1471a—a CD147-directed monoclonal antibody—in patients with advanced or metastatic solid tumors. The trial features multiple dose escalation cohorts, followed by tumor-specific expansion cohorts at the recommended Phase 2 dose.